Lenalidomide effective in chronic lymphocytic leukemia
Dec 4, 2006 - 11:19:06 AM
, Reviewed by: Himanshu Tyagi
|
|
|
Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.
|
By Roswell Park Cancer Institute (RPCI),
[RxPG] Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI).
"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.
Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.
In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.
"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.
Publication:
The results are published in the December 1 issue of the Journal of Clinical Oncology.
On the web:
www.webershandwick.com 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Blood Newsletter
|
|
|
|
Additional information about the news article
|
Roswell Park Cancer Institute, founded in 1898, is the nation’s first cancer research, treatment and education center and is the only National Cancer Institute-designated comprehensive cancer center headquartered in Upstate New York. RPCI is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers. Roswell Park has affiliate sites and collaborative programs in New York, Pennsylvania and in China.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
